Back to Search
Start Over
Roche's net rises strongly, buoyed by cancer drugs
- Source :
- Wall Street Journal. Europe. July 21, 2004
- Publication Year :
- 2004
-
Abstract
- Roche Holding AG doubles its first-half net profits thanks to strong sales of its cancer drugs and a hefty pre-tax gain that resulted from the company's having called in a bond issue. Established cancer medications, MabThera and Herceptin performed well, as did Avastin, the more recently introduced treatment for colorectal cancer.
- Subjects :
- Roche Holding AG -- Company sales and earnings
Roche Holding AG -- Mergers, acquisitions and divestments
Roche Holding AG -- Subsidiaries, divisions and units
Roche Holding AG -- Product information
Genentech Inc. -- Product information
Genentech Inc. -- Finance
Biological products industry -- Product information
Biological products industry -- Finance
Pharmaceutical industry -- Company sales and earnings
Pharmaceutical industry -- Mergers, acquisitions and divestments
Pharmaceutical industry -- Subsidiaries, divisions and units
Pharmaceutical industry -- Product information
Company product acquisition
Company financing
Company acquisition/merger
Company earnings/profit
Banking, finance and accounting industries
Business
Business, international
Subjects
Details
- Language :
- English
- ISSN :
- 09219986
- Database :
- Gale General OneFile
- Journal :
- Wall Street Journal. Europe
- Publication Type :
- News
- Accession number :
- edsgcl.119576543